Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HERC4 suppresses colorectal cancer progression

ABSTRACT: Our study aims to identify the enzymes that interact with STAT3 and the specific sites where STAT3 undergoes ubiquitination modification.

ORGANISM(S): Homo Sapiens

SUBMITTER: Zilong Zhang

PROVIDER: PXD077280 | iProX | Thu Apr 16 00:00:00 BST 2026

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

HERC4 suppresses colorectal cancer progression by promoting STAT3 ubiquitination.

Jiang Lanzhu L Qin Kaidi K Jin Yuan Y Zhu Tong T Xie Tianci T Yin Lanlan L Deng Yu Y Hu Fayong F Wu Qi Q Zhang Zilong Z

iScience 20260611 6

Ubiquitination, a critical post-translational modification, regulates diverse cellular processes including protein degradation, signal transduction, and cell cycle progression. Dysregulation of the ubiquitin system is closely associated with tumor development and progression. HERC4, a member of the HECT-type E3 ubiquitin ligase family, remains poorly characterized in colorectal cancer (CRC). In this study, we report that HERC4 is significantly downregulated in CRC tissues and is associated with ...[more]

PMID: 42325274

Similar Datasets

HERC4 suppresses colorectal cancer progression by promoting STAT3 ubiquitination

Project description:Our study aims to identify the enzymes that interact with STAT3 and the specific sites where STAT3 undergoes ubiquitination modification.

2026-03-24 | PXD076133 |

Notch signaling suppresses the progression of colorectal tumorigenesis

Project description:The Notch signaling pathway regulates fate decision, proliferation and differentiation of intestinal epithelial cells. However, the role of Notch signaling in colorectal cancer progression is largely unknown. Here we show that Notch signaling suppresses the progression of colorectal tumorigenesis, even though it augments tumor initiation. In contrast to adenomas of Apcmin mice, Notch-inactivated Apcmin adenomas showed more malignant characteristics, such as submucosal invasion and loss of glandular pattern. Conversely, Notch-activated Apcmin adenomas showed a reversion from high-grade to low-grade features, such as the restoration of adherent junctions. Expression profiling revealed that Notch signaling promotes the differentiation of tumor cells with down regulation of Wnt/beta-catenin target genes and inhibition of epithelial-mesenchymal transition. Comparison of mouse and human expression profiles also suggests the common role of Notch in inhibition of tumor progression. Interestingly, Notch signaling suppressed the expression of beta-catenin responsive genes through chromatin modification of Tcf4/beta-catenin binding sides. Our results suggest that Notch signaling has dual roles in colorectal tumorigenesis: promoting adenoma initiation, while inhibiting tumor progression to colorectal cancer. mRNAs from normal (WT, Notch-activated and Notch-inactivated) and tumor (WT, Notch-activated and Notch-inactivated) tissues were profiled.

2011-04-19 | E-GEOD-21392 | biostudies-arrayexpress

OTUD1 downregulates PD-L1 expression by deubiquitinating STAT3 and promotes the immune response in ccRCC

Project description:Renal cell carcinoma (RCC) is a common urinary malignancy. It has the highest mortality rate among urologic malignancies, and its incidence has been increasing in recent years, and its common subtype is renal clear cell carcinoma (ccRCC). Ovarian tumor domain protease 1 (OTUD1) is known as a member of the OTUD deubiquitinase family and has the ability to remove ubiquitin modifications from target proteins. The OTUD family consists of 10 members, including OTUD1, all of which have the function of deubiquitinating target proteins. In this study, we determined the correlation between OTUD1 and the immune pathway through bioinformatics analysis. Subsequently, by mass spectrometry analysis and immunoprecipitation experiments, we demonstrated that OTUD1 can interact with STAT3 and regulate the expression of PD-L1 in kidney cancer cells through STAT3. OTUD1 can also inhibit the activity and nuclear translocation of STAT3 by regulating the K63 ubiquitination modification of STAT3. Finally, we found that OTUD1 can deubiquitinate STAT3 and inhibit its activity and nuclear translocation, thereby regulating the PD-1 signaling pathway, and ultimately promoting the immune response of renal cancer tumors.

2025-12-02 | GSE249822 | GEO

Notch signaling suppresses the progression of colorectal tumorigenesis

2011-04-19 | GSE21392 | GEO

Targeting the UFL1-AKT Cascade Suppresses Triple-Negative Breast Cancer Progression

Project description:Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease with limited therapeutic options. While UFL1-mediated UFMylation has been implicated in various diseases, its role in TNBC remains unexplored. In this study, we demonstrate that AKT1 directly interacts with UFL1 and undergoes UFMylation at Lys189, Lys276, and Lys297. This modification enhances AKT phosphorylation and activation, promoting tumor growth and chemoresistance in TNBC. In turn, AKT phosphorylates UFL1 at Thr426, establishing a positive feedback loop that sustains high activity of both pro-oncogenic regulators in TNBC. Disrupting the UFL1-AKT interaction using the specific peptide PDAU-TAT significantly inhibits TNBC progression both in vitro and in vivo. Clinically, elevated pT426 UFL1 expression significantly correlates with increased pAKT levels in TNBC specimens. These findings uncover a crucial positive feedback loop between UFL1 and AKT that drives TNBC progression and suggest that targeting the UFL1-AKT axis could offer a promising therapeutic strategy for TNBC and potentially other aggressive cancers characterized by upregulated UFL1 and AKT activation.

2025-11-12 | PXD062168 | Pride

PSY Suppresses Colorectal Cancer Progression by Targeting Oncogenic Signaling and Metabolic Reprogramming

Project description:Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality, driven by dysregulated oncogenic signaling and metabolic reprogramming. PSY, an herbal formula derived from Patriniae Radix, Coix Seed, and Mori Cortex Radicis, has shown potential anti-cancer effects, but its mechanisms in CRC remain unclear. Purpose: PSY’s multi-targeted effects on oncogenic signaling, metabolic pathways, and inflammation in CRC. Materials and Methods: Transcriptomic profiling (RNA sequencing), in vitro assays, and in vivo xenograft models were used to elucidate PSY’s mechanisms. Metabolic profiling via LC-MS/MS and serum lipid analysis were performed to assess its impact on lipid metabolism. Results: PSY activated the PERK/eIF2α/ATF4 stress pathway and suppressed PI3K/Akt/mTOR signaling, inducing apoptosis and inhibiting CRC cell proliferation. Xenograft models showed significant tumor growth suppression and reduced proliferation (Ki67) and inflammation markers (COX2, p-STAT3). Metabolic profiling revealed reduced cholesterol and fatty acid biosynthesis, including arachidonic acid, correlating with COX2 downregulation. Serum LDL and HDL levels decreased, with an increased LDL/HDL ratio. Conclusion: PSY demonstrates potential as a multi-targeted agent by disrupting oncogenic signaling, lipid metabolism, and inflammation in CRC. These findings support its further exploration for clinical applications.

2026-01-05 | GSE285901 | GEO

OTUD4 suppresses colorectal cancer progression through deubiquitinating p53.

Project description: Not available

| S-EPMC12748370 | biostudies-literature

SMARCA3 is a histone H3K23 ubiquitin ligase that regulates H3K9me3 in colorectal cancer

Project description:Histone ubiquitination is an important post-translational modification (PTM) that mediates diverse chromatin functions1-3. However, our understanding of the enzymes that regulate histone ubiquitination, along with their relationships to human disease, remains limited. Here, we identify the tumor suppressor SMARCA3 as a histone H3K23 E3 ubiquitin ligase that functions through a distinct mechanism from its characterized role in post-replication repair. We show that cellular depletion of SMARCA3 results in reduced H3K9me3 levels and altered genomic distribution, leading to cancer-associated rewiring of cellular transcriptional programs . Using both cell lines and patient-derived organoids, we demonstrate that colorectal cancer tumors driven by downregulation of SMARCA3 display similar decreases in H3K9me3, as well as alterations in the expression of cancer-promoting genes. Taken together, our data indicate critical roles for SMARCA3 in maintaining chromatin integrity, and provide a mechanism through which its normal tumor-suppression function may precipitate colorectal cancer when perturbed.

2023-06-05 | GSE151913 | GEO

VCPIP1 facilitates pancreatic cancer progression via Hippo/YAP signaling

Project description:The dys-regulation of Hippo signaling was observed in pancreatic adenocarcinoma (PAAD), while the over-activation of YAP was crucial for tumor progression. It is unclear why YAP was hyper-activated in PAAD, although the inhibitory phospho-cascade was still functional. Recently studies revealed that the ubiquitin modification of YAP also play important roles in Hippo/YAP axis and cancer progression. In order to understand the potential mechanisms of ubiquitination and deubiquitination process in YAP function, we carried out siRNA screening for critical deubiquitinases in PAAD. Via the deubiquitinases (DUB) library, we identified Valosin Containing Protein Interacting Protein 1 (VCPIP1) as an important effector in YAP function and PAAD progression. Inhibition of VCPIP1 hampered PAAD progression via Hippo signaling. Clinical data revealed that VCPIP1 was elevated in PAAD and correlated with poor survival in PAAD patients. Biochemical assays showed that VCPIP1 could interact with YAP and inhibit K48-linked poly-ubiquitination, which subsequently increased YAP stability. Interestingly, YAP could direct bind to VCPIP1 promoter region and facilitate its transcription in PAAD. Our study revealed a forward feedback loop between VCPIP1 and Hippo signaling in PAAD, indicating VCPIP1 as a potential therapeutic drug targets in PAAD.

2024-12-19 | GSE284347 | GEO

Capicua suppresses colorectal cancer progression via repression of ETV4 expression.

Project description: Not available

| S-EPMC7003492 | biostudies-literature